First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study

Anticancer Research

Volumn 21, Issue 5, 2001, Pages 3575-3580

  Pectasides, D ^a   Dimopoulos, M A ^a   Aravantinos, G ^a   Kalophonos, H P ^a   Papacostas, P ^a   Briasoulis, E ^a   Cogas, E ^a   Papadimitriou, Ch ^a   Skarlos, D ^a   Kosmidis, P ^a   Fountzilas, G ^a  

^a Hellenic Cooperative Oncology Group   (Greece)

Author keywords

Breast cancer; Combination chemotherapy; Docetaxel; Vinorelbine

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; STEROID;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; METASTASIS; NEUTROPENIA; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS; VINBLASTINE;

EID: 0035571833     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Systemic therapy for advanced breast cancer
2. Relationships between the structure of taxol analogues and their antitumor activity
3. Studies with PR-56976 (Taxotere): A semisynthetic analogue of Taxol
4. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer. A phase II trial of the clinical screening Cooperative Group of the European Organization for research and treatment of cancer
5. Phase II studies and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
6. Multicentre phase II study of the efficacy and safety of docetaxel as first line treatment of advanced breast cancer. Report of the clinical screening group of the EORTC
7. Docetaxel in patients with metastatic breast cancer. A phase II study of National-Cancer Institute of Canada-Clinical Trials Group
8. Phase II first line chemotherapy (CT) study with docetaxel (Taxotere) and prophylactic premedication of fluid retention (FR) in patients (pts) with metastatic (mts) or locally advanced breast cancer (ABC)
9. The synthesis of Navelbine, prototypes of a new series of vinblastine derivatives
10. Summary of data from in vitro and phase I vinorelbine (Navelbine) studies
11. In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence
12. Phase II study of Navelbine in advanced breast cancer
13. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy
14. Phase trial of weekly II I.V. Vinorelbine in first line advanced breast cancer chemotherapy
15. Vinorelbine as first line chemotherapy for metastatic breast cancer
16. A phase II, multicentre UK study of vinorelbine in advanced breast cancer
17. Vinorelbine an active, non-cross resistant drug in advanced breast cancer: Results from a phase II study
18. Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer
19. Phase trial of weekly II I.V. vinorelbine as a single agent in first line advanced breast cancer chemotherapy. The Latin-American experience
20. Docetaxel in combination with vinorelbine: Preclinical-clinical correlation
21. Preclinical activity of navelbine and taxol drug combinations
22. Synergy of navelbine, taxol combination treatment in two human breast cancer cell lines
23. In vitro synergy of paclitaxel (taxol) and vinorelbine (navelbine) against human melanoma cell lines
24. Docetaxel combined with vinorelbine. Phase I results and new study designs
25. Non-parametric estimation for incomplete observations
26. Combination chemotherapy with carboplatin, docetaxel and gemcitabine in advanced non-small-cell lung cancer. A phase II study
27. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine. A multicentre phase II trial
28. Docetaxel (D) in combination with vinorelbine (VNB) with GM-CSF in taxol refractory metastatic breast cancer (MBC). Preliminary results of a phase II study
29. Docetaxel-Vinorelbine is an active combination for patients with anthracycline refractory metastatic breast cancer. Results of a phase II trial
30. Docetaxel and vinorelbine every 14 days in patients with metastatic breast cancer after using anthracyclines. Final results
31. A phase II study of docetaxel (D) and vinorelbine (V) in metastatic breast cancer (MBC)
32. Docetaxel and vinorelbine with concurrent G-CSF support. A phase II study in stage IV breast cancer
33. Treatment of advanced breast cancer (ABC) with docetaxel and vinorelbine ± human granulocyte colony stimulating factor (G-CSF)
34. Treatment of metastatic breast cancer. Present and future prospects
35. Paclitaxel plus vinorelbine: An active regimen in metastatic breast cancer patients with prior anthracycline exposure
36. Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer